Abbreviated Name

PCA3 Sanda-PHI

Lead Investigator

Sanda, Martin — Emory University

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Chan, Daniel — Johns Hopkins Medical Institutions
• Sanda, Martin — Emory University
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

No abstract availalbe.

Aims

In the development phase, we plan to formulate a number of rules: The first one is to linearly combine PCA3, phi, and clinical variables via logistic regression. The clinical variables include age, BMI, race, DRE result, initial biopsy indicator, number of previous negative biopsies after diagnosis, cores ratio (ratio of biopsy cores containing cancer to total cores), months since diagnosis, and prostate volume. Appropriate variable selection will be implemented in the logistic regression to screen out non-informative clinical variables. The second rule is to linearly combine PCA3, phi, and initial biopsy indicator only, without other clinical variables. Obviously, this rule is expected to have less predictive power than the first one, but can be more practical if the predictive power reduction is limited. The third rule is a “or” logic combination of PCA3, phi, and a composite score of clinical variables. The composite score is obtained via logistic regression. The fourth rule is a “or” logic combination of PCA3 and phi only.

Analytic Method

No analytic method available.

Publications

• No publications available at this time for this protocol.

Biomarkers

• PCA3
• phi/PCA3

Data Collections

• No data collections available at this time for this protocol.

Start Date

May 1 2018

Estimated Finish Date

May 1 2019

Protocol ID

453

Protocol Type

Reference Set

Fields of Research

• Proteomics

Collaborative Group

Prostate and Urologic Cancers Research Group

Cancer Types

• Malignant neoplasm of prostate

Phased Status

2